EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Plans underway to expand screening capacity by 50% for greater accessibility
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Subscribe To Our Newsletter & Stay Updated